

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/835,298
Filing Date	4/13/2001
First Named Inventor	Jeffrey R. Dahlen
Group Art Unit	1641
Examiner Name	Lam, Ann Y.
Attorney Docket Number	071949-5301

Sheet

1

of

1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
cc	A	5,206,140		Marder et al.	04-27-1993	
	B	6,309,888		Holvoet et al.	10-30-2001	
	C	6,461,828		Stanton et al.	10-08-2002	
	D					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	E							
	F							
	G							

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
cc	H	SAADY et al., "Left appendage: structure function, and role in thromboembolism," Heart, 1999, pp. 547-555, Vol. 82	
	I		
	J		
	K		
	L		
	M		

Examiner
Signature

Date
Considered


3/9/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DLMR_277634.1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 27, 2005 (use as many sheets as necessary)		Complete if Known	
		Application Number	09/835,298
		Filing Date	04/13/2001
		First Named Inventor	Jeffrey R. Dahlen
		Group Art Unit	1641
		Examiner Name	Ann Y. Lam
		Attorney Docket Number	071949-5301

Sheet 1 of 11

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
AL	A1	5,747,274		JACKOWSKI	05/05/1998	
	A2	5,604,105		JACKOWSKI	02/18/1997	
	A3	5,786,163		HALL	07/28/1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
AL	A4	Party Stanton Proofs of Invention for Interference 105,167.	
	A5	Declaration of George Jackowski, Interference No. 105,167.	
	A6	Declaration of Dr. A. Mark Richards, Interference No. 105,167.	
	A7	Declaration of Eric Stanton, Interference No. 105,167.	
AL	A8	AL-AHMAD et al., Reduced Kidney Function and Anemia as Risk Factors for Mortality in Patients With Left Ventricular Dysfunction, Journal of the American College of Cardiology, October 2001, pp. 955-962, Vol. 38, No. 4, Elsevier Science Inc.	

Examiner Signature		Date Considered	3/12/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 27, 2005 <i>(use as many sheets as necessary)</i>		Application Number	09/835,298
		Filing Date	04/13/2001
		First Named Inventor	Jeffrey R. Dahlen
		Group Art Unit	1641
		Examiner Name	Ann Y. Lam
Sheet	2	of	11
		Attorney Docket Number	071949-5301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
OL	A9	ALTEMOSE et al., Altered Myocardial Phenotype After Mechanical Support in Human Beings with Advanced Cardiomyopathy, The J. of Heart and Lung Transplantation, July 1997, pp. 765-773, Vol. 16, No. 7.	
	A10	ANDO et al., Plasma Concentrations of Atrial, Brain, and C-type Natriuretic Peptides and Endothelin-1 in Patients With Chronic Respiratory Diseases, CHEST, August 1996, pp. 462-468, Vol. 110, No. 2.	
	A11	APPLE et al., Myocardial Infarction Redefined: Role of Cardiac Troponin Testing, Clinical Chemistry, 2001, pp. 377-379, Vol. 47, No. 3.	
	A12	ARAKAWA et al., Relationship between Plasma Level of Brain Natriuretic Peptide and Myocardial Infarct Size, Cardiology, November 1994, pp. 334-340, Vol. 85, No. 5.	
	A13	ARAKAWA et al., Plasma Brain Natriuretic Peptide Concentrations Predict Survival After Acute Myocardial Infarction, J. Am. Coll. Cardiol., June 1996, pp. 1656-61, Vol. 27, No. 7, Elsevier Science Inc.	
	A14	BALLERMANN, Amer. J. of Physiology, January 1988, pp. F159-F163, Vol. 254, No. 1, Part 2 of Two Parts, The American Physiological Society.	
	A15	BELLORINI et al., Interest of BNP and Troponin in the Management of Cardiac Emergency, J. of European Society of Cardiology, September 1-5, 2001, p. 518, Vol. 22.	
	A16	BLOMKALNS et al., Markers and the Initial Triage and Treatment of Patients with Chest Pain, Cardiovascular Toxicology, 2001, pp. 111-115, Vol. 1, No. 2, Humana Press.	
	A17	BOLLI et al., Myocardial Protection at a Crossroads: The Need for Translation Into Clinical Therapy, Circulation Research, July 23, 2004, pp. 125-134.	
	A18	BOOMSMA et al., Plasma A- and B-type Natriuretic Peptides: Physiology, Methodology and Clinical Use, Cardiovascular Research, 2001, pp. 442-449, Vol. 51, Elsevier.	
	A19	BRUCCOLERI et al., Brain Natriuretic Peptide in Patients with Acute Myocardial Infarction and Hypertension, Clin Chem Lab Med, June 1999, Special Supplement, p. S440, Vol. 37.	
	A20	DE BRUYNE et al., Prolonged QT Interval Predicts Cardiac and All-Cause Mortality in the Elderly, Eur Heart J, February 1999, pp. 278-284, Vol. 20, No. 4.	
	A21	BÜRGISSE et al., Human Cardiac Plasma Concentrations of Atrial Natriuretic Peptide Quantified by Radioreceptor Assay, Biochemical and Biophysical Research Communications, December 31, 1985, pp. 1201-1209, Vol. 133, No. 3, Academic Press, Inc.	
△	A22	CAMERON et al., Natriuretic Peptide System in Fetal Heart and Circulation, Journal of Hypertension, 2002, pp. 801-803, Vol. 20, No. 5.	

Examiner Signature		Date Considered	3/12/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 27, 2005 <i>(use as many sheets as necessary)</i>		Application Number	09/835,298
		Filing Date	04/13/2001
		First Named Inventor	Jeffrey R. Dahlen
		Group Art Unit	1641
		Examiner Name	Ann Y. Lam
Sheet	3	of	11
		Attorney Docket Number	071949-5301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
OK	A23	CANNON et al., Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial, Circulation, July 11, 2000, pp. 149-156.	
	A24	CANNON et al., ACC Clinical Data Standards, American College of Cardiology Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients with Acute Coronary Syndromes, J. Am. Coll. Cardiol., December 2001, pp. 2114-30, Vol. 38, No. 7, Elsevier Science Inc.	
	A25	CANTIN et al., The Heart and the Atrial Natriuretic Factor, Endocrine Reviews, Spring 1985, pp. 107-127, Vol. 6, No. 2.	
	A26	CHEN et al., The Natriuretic Peptides in Heart Failure: Diagnostic and Therapeutic Potentials, Proceedings of the Assoc of American Physicians, September/October 1999, pp. 406-416, Vol. 111, No. 5.	
	A27	CHU et al., A Review of Clinically Relevant Cardiac Biochemical Markers, Wisconsin Medical Journal, 2002, pp. 40-48, Vol. 101, No. 3.	
	A28	CLERICO et al., Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review, Clinical Chemistry, 2004, pp. 33-50, Vol. 50, No. 1.	
	A29	COLLINSON et al., Measurement of Cardiac Troponins, Am Clin Biochem, September 2001, pp. 423-449, Vol. 38, The Royal Society of Medicine Press.	
	A30	CROAL et al., Brain Natriuretic Peptide and Cardiac Troponin I as Markers of Doxorubicin Cardiotoxicity, Journal of the American Society of Hematology, November 16, 2000, Part 2 of 2 Parts, pp. 239b, Vol. 96, No. 11	
	A31	CROAL et al., Cardiac Troponin I and Brain Natriuretic Peptide as Markers of Doxorubicin Cardiotoxicity, Clinical Chemistry, 2001, Supplement, p. A149, Vol. 47, No. 6.	
	A32	DARBAR et al., Diagnostic Value of B-Type Natriuretic Peptide Concentrations in Patients With Acute Myocardial Infarction, The American Journal of Cardiology, August 1, 1996, pp. 284-287, Vol. 78.	
	A33	DAVIDSON et al., C-Type Natriuretic Peptide, An Endogenous Inhibitor of Vascular Angiotensin-Converting Enzyme Activity, Circulation, 1996, pp. 1155-1159, Vol. 93.	
	A34	DAVIDSON et al., Comparison of Atrial Natriuretic Peptide, B-Type Natriuretic Peptide, and N-Terminal Proatrial Natriuretic Peptide as Indicators of Left Ventricular Systolic Dysfunction, The American Journal of Cardiology, April 15, 1996, pp. 828-831, Vol. 77.	
	A35	DE BOLD A.J., Atrial Natriuretic Factor: A Hormone Produced by the Heart, Science, Nov. 15, 1985, pp. 767-770, Vol. 230.	
	A36	DE LEMOS et al., The Prognostic Value of B-Type natriuretic Peptide in Patients with Acute Coronary Syndromes, N. Engl. J. Med., October 4, 2001, pp. 1014-1021, Vol. 345, No. 14, Massachusetts Medical Society.	

Examiner Signature		Date Considered	3/12/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/835,298
		Filing Date	04/13/2001
Date Submitted: October 27, 2005 (use as many sheets as necessary)		First Named Inventor	Jeffrey R. Dahlen
		Group Art Unit	1641
Sheet 4 of 11		Examiner Name	Ann Y. Lam
		Attorney Docket Number	071949-5301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A37	DE LEMOS et al., Combining Natriuretic Peptides and Necrosis Markers in the Assessment of Acute Coronary Syndromes, Reviews in Cardiovascular Medicine, 2003, pp. S37-S46, Vol. 4, Supp. 4.	
	A38	DOMANSKI et al., A Comparative Analysis of the Results From 4 Trials of β -Blocker Therapy for Heart Failure: BEST, CIBIS-II, MERIT-HF, and CORPERNICUS, J. of Cardiac Failure, October 2003, pp. 354-363, Vol. 9, No. 5.	
	A39	DONALDSON et al., Cardiac Troponin Levels in Patients with Impaired Renal Function, Hospital Medicine, February 2001, pp. 86-89, Vol. 62, No. 2.	
	A40	FONAROW et al., Combining Natriuretic Peptides and Necrosis Markers in Determining Prognosis in Heart Failure, Reviews in Cardiovascular Medicine, 2003, pp. S20-S28, Vol. 4, Suppl. 4.	
	A41	FREEMANTLE et al., Composite Outcomes in Randomized Trials: Greater Precision But With Greater Uncertainty? JAMA, May 21, 2003, pp. 2554-2559, Vol. 289, No. 19 (Reprinted).	
	A42	GOLDACRE et al., Multiple-cause Coding of Death from Myocardial Infarction: Population-Based Study of Trends in Death Certificate Data, Journal of Public Health Medicine, March 2003, pp. 69-71, Vol. 25, No. 1, Oxford University Press, Great Britain	
	A43	GUTKOWSKA et al., Radioreceptor Assay for Atrial Natriuretic Factor, Analytical Biochemistry, January 1988, pp. 100-106, Vol. 168, No. 1, Academic Press, Inc.	
	A44	HAMPTON et al., Achieving Appropriate Endpoints in Heart Failure Trials: the PRIME-II Protocol, The European Journal of Heart Failure, 1999, pp. 89-93, Vol. 1.	
	A45	HAMMERER-LECHER et al., Head-to-Head Comparison of N-terminal Pro-brain Natriuretic Peptide, Brain Natriuretic Peptide and N-terminal Pro-atrial Natriuretic Peptide in Diagnosing Left Ventricular Dysfunction, Clinica Chimica Acta, 2001, pp. 193-197, Vol. 310.	
	A46	HOLMES, JR. et al., Cause of Death Analysis in the NHLBI PTCA Registry: Results and Considerations for Evaluating Long-Term Survival After Coronary Interventions, J. Am. Coll. Cardiol., October 1997, pp. 881-887, Vol. 30, No. 4, Elsevier Science Inc.	
	A47	HORIO et al., Serial Changes in Atrial and Brain Natriuretic Peptides in Patients with Acute Myocardial Infarction Treated with Early Coronary Angioplasty, American Heart Journal, August 1993, pp. 293-299, Vol. 126, No. 2.	
	A48	HUNT et al., Bioactivity and Metabolism of C-Type Natriuretic Peptide in Normal Man, J Clin Endocrinol Metab, 1994, pp. 1428-1435, Vol. 78, No. 6.	
	A49	HUNT et al., Differing Biological Effects of Equimolar Atrial and Brain Natriuretic Peptide Infusions in Normal Man, J Clin Endocrinol Metab, 1996, pp. 3871-76, Vol. 81, No. 11.	
	A50	HWANG et al., Analysis of Expressed Sequence Tags from a Fetal Human Heart cDNA Library, Genomics, 1995, pp. 293-298, Vol. 30.	

Examiner Signature		Date Considered	3/12/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/835,298
		Filing Date	04/13/2001
Date Submitted: October 27, 2005 (use as many sheets as necessary)		First Named Inventor	Jeffrey R. Dahlen
		Group Art Unit	1641
Sheet 5 of 11		Examiner Name	Ann Y. Lam
		Attorney Docket Number	071949-5301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
cl	A51	IKRAM et al., An Ovine Model of Acute Myocardial Infarction and Chronic Left Ventricular Dysfunction, Angiology, Aug. 1997, Vol. 48, No. 8, 1 page abstract retrieved on-line on Jul 27, 2004.	
	A52	ISHII et al., Risk Stratification Using Cardiac Troponin T in Patients with End-Stage Renal Disease, Supplement to Circulation, Journal of the American Heart Association, November 7-10, 1999, Abstracts from the 72 nd Scientific Sessions, p. I-177.	
	A53	ISHII et al., Early Risk Stratification Using Cardiac Troponin T and Brain Natriuretic Peptide in Patients with Congestive Heart Failure, Supplement to Circulation, Journal of the American Heart Association, November 7-10, 1999, Abstracts from the 72 nd Scientific Sessions, p. I-679.	
	A54	ISHII et al., Risk Stratification Using Serum Concentrations of Cardiac Troponin T in Patients with end-stage Renal Disease on Chronic Maintenance Dialysis, Clinica Chimica Acta, 2001, pp. 69-79, Vol. 312.	
	A55	ISHII et al., Risk Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Hospitalized for Worsening Chronic Heart Failure, The American Journal of Cardiology, March 15, 2002, pp. 691-695, Vol. 89.	
	A56	ITOH et al., Occurrence of a Novel Cardiac Natriuretic Peptide in Rats, Biochemical and Biophysical Research Communications, June 15, 1989, pp. 732-739, Vol. 161, No. 2.	
	A57	JAFFE A.S., New Standard for the Diagnosis of Acute Myocardial Infarction, Cardiology in Review, 2001, p. 318-322, Vol. 9, No. 6.	
	A58	JANCIN B., Rapid test Helps Identify Cause of Dyspnea - Point-of-Care Brain Natriuretic Peptide Immunoassay, [on-line]. Retrieved from the Internet 10/18/2004: <URL: http://www.findarticles.com/p/articles/mi_m0BJI/is_9_30/ai_63125276/ >, 2 pages.	
	A59	JOURDAIN et al., B Type Natriuretic Peptide and Cardiac Troponin I in Acute Chest Pain, October 21-24, 2001, Advances in Coronary Artery Disease, Proceedings of the 4 th International Congress on Coronary Artery Disease, pp. 509-515.	
	A60	KARRAS et al., Serum Markers in the Emergency Department Diagnosis of Acute Myocardial Infarction, Emergency Medicine Clinics of North America, May 2001, pp. 321-337, Vol. 19, No. 2, W.B. Saunders Company.	
	A61	KELLY et al., Are Natriuretic Peptides Clinically Useful as Markers of Heart Failure?, Ann. Clin. Biochem., 2001, pp. 94-102, Vol. 38.	
	A62	KLINGER et al., C-type Natriuretic Peptide Expression and Pulmonary Vasodilation in Hypoxia-adapted Rats, Am. J. Physiol, Vol. 275 (Lung Cell Mol Physiol), 1998, pp. L645-L652.	
	A63	LAINCHBURY et al., Brain Natriuretic Peptide and N-Terminal Brain Natriuretic Peptide in the Diagnosis of Heart Failure in Patients With Acute Shortness of Breath, J. Am. Coll. Cardiol., August 20, 2003, pp. 728-35, Vol. 42, No. 4, Elsevier Inc.	
	A64	LARAGH J.H., Atrial Natriuretic Hormone, the Renin-Aldosterone Axis, and Blood Pressure-electrolyte Homeostasis, The New England Journal of Medicine, November 21, 1985, pp. 1330-40, Vol. 313, No. 21, Massachusetts Medical Society.	

Examiner Signature		Date Considered	3/12/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 27, 2005 <i>(use as many sheets as necessary)</i>		Application Number	09/835,298
		Filing Date	04/13/2001
		First Named Inventor	Jeffrey R. Dahlen
		Group Art Unit	1641
		Examiner Name	Ann Y. Lam
Sheet	6	of	11
		Attorney Docket Number	071949-5301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
AL	A65	CIBIS-II INVESTIGATORS AND COMMITTEES, The Cardiac Insufficiency Biosprolol Study II (CIBIS-II): A Randomised Trial, The Lancet, January 2, 1999, pp. 9-13, Vol. 353.	
	A66	Li et al., Greater Frequency of Increased Cardiac Troponin T Than Increased Cardiac Troponin I in Patients with Chronic Renal Failure, Clinical Chemistry, 1996, pp. 114-15, Vol. 42, No. 1.	
	A67	LIEW et al., A Catalogue of Genes in the Cardiovascular System as Identified by Expressed Sequence Tags, Proc. Natl. Acad. Sci. USA, October 1994, pp. 10645-10649, Vol. 91.	
	A68	Lindahl, B., N. Engl. J. Med., November 22, 2001, pp. 1579-1580, Vol. 345, No. 21, Massachusetts Medical Society.	
	A69	LUCHNER et al., Differential Atrial and Ventricular Expression of Myocardial BNP During Evolution of Heart Failure, pp. H1684-H1689 (1998).	
	A70	MAEDA et al., High levels of Plasma Brain Natriuretic Peptide and Interleukin-6 After Optimized Treatment for Heart Failure are Independent Risk Factors for Morbidity and Mortality in Patients with Congestive Heart Failure, J. Am. Coll. Cardiol., November 1, 2000, pp. 1587-93, Vol. 36, No. 5, Elsevier Science Inc.	
	A71	MAISEL A., Cardiac Biomarkers Aid in Diagnosing Ischemia and Heart Failure, CVR&R, April 2001, pp. 217-222, Vol. 22, No. 4.	
	A72	MANNING et al., The Protein Kinase Complement of the Human Genome, Science, December 6, 2002, pp. 1912-1916 and 1933-1934, Vol. 298.	
	A73	MÄNTYMAA et al., Atrial Stretch Induces Rapid Increase in Brain Natriuretic Peptide But Not in Atrial Natriuretic Peptide Gene Expression In Vitro, Endocrinology, 1993, pp. 1470-1473, Vol. 133, No. 3.	
	A74	MARTIN et al., Estimation of Myocardial Infarction Mortality from Routinely Collected Data in Western Australia, J. Chron. Dis., 1987, pp. 661-669, Vol. 40, No. 7, Great Britain.	
	A75	McCULLOUGH et al., Performance of Multiple Cardiac Biomarkers Measured in the Emergency Department in Patients with Chronic Kidney Disease and Chest Pain, Acad. Emerg. Med., December 2002, pp. 1389-96, Vol. 9, No. 12.	
	A76	McCULLOUGH et al., B-Type Natriuretic Peptide and Renal Function in the Diagnosis of Heart Failure: An Analysis From the Breathing Not Properly Multinational Study, American Journal of Kidney Diseases, March 2003, pp. 571-579, Vol. 41, No. 3.	
	A77	McCULLOUGH et al., Risks Associated With Renal Dysfunction in Patients in the Coronary Care Unit, J. Am. Coll. Cardiol., September 2000, pp. 679-84, Vol. 36, No. 3, Elsevier Science Inc.	
	A78	McCULLOUGH P.A., Beyond Serum Creatinine: Defining the Patient with Renal Insufficiency and Why?, Reviews in Cardiovascular Medicine, 2003, pp. S2-S6, Vol. 4, Supp. 1.	

Examiner Signature		Date Considered	3/12/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.















¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 27, 2005 (use as many sheets as necessary)		Application Number	09/835,298
		Filing Date	04/13/2001
		First Named Inventor	Jeffrey R. Dahlen
		Group Art Unit	1641
		Examiner Name	Ann Y. Lam
Sheet	7	of	11
		Attorney Docket Number	071949-5301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A79	McDONAGH et al., Biochemical Detection of Left-Ventricular Systolic Dysfunction, The Lancet, January 3, 1998, p. 9-13, Vol. 351.	
	A80	McGEOCH et al., Plasma Brain Natriuretic Peptide After Long-Term Treatment for Heart Failure in General Practice, The European Journal of Heart Failure, 2002, pp. 479-483, Vol. 4, Elsevier Science B.V.	
	A81	MICHENER et al., Proteolytic Processing of Atriopeptin Prohormone, Molecular Pharmacology, December 1986, pp. 552-557, Vol. 30, No. 6, Am. Society for Pharmacology and Experimental Therapeutics.	
	A82	MOE et al., Neurohormonal Activation in Severe Heart Failure: Relations to Patient Death and the Effect of Treatment with Flosequinan, American Heart Journal, April 2000, pp. 587-595, Vol. 139, No. 4.	
	A83	MUKOYAMA et al., Increased Human Brain Natriuretic Peptide in Congestive Heart Failure, The New England Journal of Medicine, September 13, 1990, pp. 757-758, Vol. 323, No. 11, Massachusetts Medical Society.	
	A84	NAGAYA et al., Plasma Brain natriuretic Peptide as a Prognostic Indicator in Patients with Primary Pulmonary Hypertension, Circulation, August 22, 2000, pp. 865-870, Vol. 102.	
	A85	NAGHAVI et al., From Vulnerable Plaque to Vulnerable Patient; A Call for New Definitions and Risk Assessment Strategies: Part I, Circulation, October 7, 2003, pp. 1664-1672, Vol. 108.	
	A86	NAGHAVI et al., From Vulnerable Plaque to Vulnerable Patient; A Call for New Definitions and Risk Assessment Strategies: Part II, Circulation, October 14, 2003, pp. 1772-1778, Vol. 108.	
	A87	NEEDLEMAN et al., Atriopeptins as Cardiac Hormones, Hypertension, July-August 1985, p. 469-82, Vol. 7, No. 4.	
	A88	NI C.Y., Cardiac Troponin I: A Biomarker for Detection and Risk Stratification of Minor Myocardial Damage, Clin. Lab. 2001, pp. 483-492, Vol. 47, No. 9-10.	
	A89	NICHOLLS et al., Plasma Cardiac Natriuretic Peptide Levels in Screening for Cardiac Disease, The American Journal of Medicine, April 15, 2004, pp. 561-63, Vol. 116.	
	A90	NICHOLLS, et al., Brain Natriuretic Peptide-Guided Therapy for Heart Failure, Ann. Med., 2001, pp. 422-427, Vol. 33.	
	A91	NOLAN et al., Prospective Study of Heart Rate Variability and Mortality in Chronic Heart Failure, October 13, 1998, pp. 1510-1516, Vol. 98.	
	A92	OGAWA et al., Characterization of Natriuretic Peptide Production by Adult Heart Atria, A. J. Physiol Vol. 276 (Heart Circ. Physiol. 45):H1977-86 (1999).	

Examiner Signature		Date Considered	3/12/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 27, 2005 (use as many sheets as necessary)		Application Number	09/835,298
		Filing Date	04/13/2001
		First Named Inventor	Jeffrey R. Dahlen
		Group Art Unit	1641
		Examiner Name	Ann Y. Lam
Sheet	8	of	11
		Attorney Docket Number	071949-5301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A93	OGAWA et al., Molecular Biology and Biochemistry of Natriuretic Peptide Family, Clinical and Experimental Pharmacology and Physiology, January 1995, pp. 49-53, Vol. 22, No. 1, Blackwell Science.	
	A94	OMLAND et al., Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term Survival After Acute Myocardial Infarction, Circulation, June 1, 1996, pp. 1963-69, Vol. 93, No. 11.	
	A95	OMLAND et al., N-Terminal Pro-brain Natriuretic Peptide is An Independent Predictor of Survival in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a TIMI 11B Substudy, Journal of the European Society of Cardiology, September 2001, p. 608, Vol. 22.	
	A96	PAGANO F., Marcatori Cardiaci All' "European Meeting on Biomarkers of Organ Damage and Dysfunction" (EMBODY 2000), Riv. Med. Lab. - JLM., Oct.-Dec. 2000, pp. 72-73, Vol. 1, No. 4.	
	A97	PALMER et al., Angiotensin-Converting Enzyme Gene Polymorphism Interacts With Left Ventricular Ejection Fraction and Brain Natriuretic Peptide Levels to Predict Mortality After Myocardial Infarction, J. Am. Coll. Cardiol., March 5, 2003, pp. 729-36, Vol. 41, No. 5, Elsevier Science, Inc.	
	A98	PRATT et al., Exploration of the Precision of Classifying Sudden Cardiac Death, Circulation, February 1, 1996, pp. 519-24, Vol. 93, No. 3.	
	A99	PRICKETT et al., Identification of Amino-Terminal Pro-C-Type Natriuretic Peptide in Human Plasma, Biochemical and Biophysical Research Communications, 2001, pp. 513-17, Vol. 286, No. 3.	
	A100	RADEMAKER et al., Cardiac Natriuretic Peptides for Cardiac Health, Clinical Science Immediate Publication, October 12, 2004, pp. 1-35.	
	A101	RICCHIUTI et al., Cardiac Troponin T Isoforms Expressed in Renal Diseased Skeletal Muscle Will Not Cause False-Positive Results by the Second Generation Cardiac Troponin T Assay by Boehringer Mannheim, Clinical Chemistry, 1998, pp. 1919-1924, Vol. 44, No. 9.	
	A102	RICHARDS et al., Plasma N-Terminal Pro-Brain Natriuretic Peptide and Adrenomedullin; New Neurohormonal Predictors of Left Ventricular Function and Prognosis After Myocardial Infarction, May 19, 1998, pp. 1921-1929, Vol. 97.	
	A103	RICHARDS A.M., The Natriuretic Peptides in Heart Failure, Basic Res. Cardiol., 2004, pp. 94-100, Vol. 99, No. 2.	
	A104	RICHARDS et al., B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction, Circulation, June 10, 2003, pp. 2786-92, Vol. 107.	
	A105	RICHARDS et al., Neuroendocrine Prediction of Left Ventricular Function and Heart Failure After Acute Myocardial Infarction, Heart, 1999, pp. 114-120, Vol. 81.	
	A106	RICHARDS et al., BNP in Hormone-Guided Treatment of Heart Failure, Trends in Endocrinology & Metabolism, May/June 2002, pp. 151-155, Vol. 13, No. 4.	

Examiner Signature		Date Considered	7/12/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/835,298
		Filing Date	04/13/2001
Date Submitted: October 27, 2005 (use as many sheets as necessary)		First Named Inventor	Jeffrey R. Dahlen
		Group Art Unit	1641
Sheet 9 of 11		Examiner Name	Ann Y. Lam
		Attorney Docket Number	071949-5301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
OK	A107	RICHARDS et al., Clinical Applications of B-Type Natriuretic Peptides, Trends in Endocrinology & Metabolism, May 2004, pp. 170-74, Vol. 15, No. 4, Elsevier.	
	A108	SABATINE et al., Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes, Circulation, April 16, 2002, pp. 1760-63, Vol. 105.	
	A109	SAGNELLA et al., Atrial Natriuretic Peptide in Human Plasma - Comparison of Radioreceptor Versus Radioimmunoassay, Clinica Chimica Acta, June 30, 1987, pp. 37-44, Vol. 166, No. 1, Elsevier.	
	A110	SAITO et al., Brain Natriuretic Peptide is a Novel Cardiac Hormone, Biochemical and Biophysical Research Communications, January 31, 1989, pp. 360-368, Vol. 158, No. 2.	
	A111	Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Amer. J. Kidney Diseases, February 2002, pp. S46-S110, Vol. 39, No. 2, Supp. 1.	
	A112	SELVAIS et al., Cardiac Natriuretic Peptides for Diagnosis and Risk Stratification in Heart Failure: Influences of Left Ventricular Dysfunction and Coronary Artery Disease on Cardiac Hormonal Activation, European Journal of Clinical Investigation, 1998, pp. 636-642, Vol. 28.	
	A113	SELVAIS et al., Direct Comparison Between Endothelin-1, N-Terminal Proatrial Natriuretic Factor, and Brain Natriuretic Peptide as Prognostic Markers of Survival in Congestive Heart Failure, Journal of Cardiac Failure, September 2000, pp. 201-207, Vol. 6, No. 3.	
	A114	SELVIN S., Statistical analysis of Epidemiologic Data, Monographs in Epidemiology and Biostatistics, 1991, pp. 226 and 230, Vol. 17, Oxford University Press, Inc.	
	A115	SMITH et al., Delayed Metabolism of Human Brain Natriuretic Peptide Reflects Resistance to Neutral Endopeptidase, Journal of Endocrinology, 2000, pp. 239-248, Vol. 167, Society for Endocrinology, Great Britain.	
	A116	STEIN et al., Natriuretic Peptides: Physiology, Therapeutic Potential, and Risk Stratification in Ischemic Heart Disease, American Heart Journal, May 1998, pp. 914-923, Vol. 135, No. 5, Part 1.	
	A117	SUDOH et al., A New Natriuretic Peptide in Porcine Brain, Nature, March 3, 1988, pp. 78-81, Vol. 332, No. 6159.	
	A118	SUNDSFJORD et al., Identification and Plasma Concentrations of the N-Terminal Fragment of Proatrial Natriuretic Factor in Man, J Clin Endocrinol Metab, March 1988, pp. 605-610, Vol. 66, No. 3.	
	A119	TAKASE, Myocardial Micro-Damage in Acute Heart Failure, Journal of Submicroscopic Cytology and Pathology, July 2000, p. 379, Abstract A161, Vol. 32, No. 3.	
	A120	TAKEMURA et al., Ventricular Expression of Atrial and Brain Natriuretic Peptides in Patients with Myocarditis, International Journal of Cardiology, 1995, pp. 213-222, Vol. 52.	

Examiner Signature		Date Considered	3/2/06
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 27, 2005 <i>(use as many sheets as necessary)</i>		Application Number	09/835,298
		Filing Date	04/13/2001
		First Named Inventor	Jeffrey R. Dahlen
		Group Art Unit	1641
		Examiner Name	Ann Y. Lam
Sheet	10	of	11
		Attorney Docket Number	071949-5301

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A121	TAKEMURA et al., Expression of Atrial and Brain Natriuretic Peptides and Their Genes in Hearts of Patients with Cardiac Amyloidosis, J. Am. Coll. Cardiol., March 15, 1998, pp. 754-65, Vol. 31, No. 4, Elsevier Science Inc.	
	A122	TALWAR et al., Profile of Plasma N-Terminal proBNP Following Acute Myocardial Infarction; Correlation with Left Ventricular Systolic Dysfunction, Eur. Heart J., September 2000, pp. 1514-1521, Vol. 21, No. 18.	
	A123	TANAKA et al., Cellular Localization and Structural Characterization of Natriuretic Peptide-Expressing Ventricular Myocytes from Patients with Dilated Cardiomyopathy, Journal of Histochemistry and Cytochemistry, 1994, pp. 1207-1214, Vol. 42, No. 9, USA.	
	A124	THE JOINT EUROPEAN SOCIETY OF CARDIOLOGY/AMERICAN COLLEGE OF CARDIOLOGY COMMITTEE, Consensus Document, Myocardial Infarction Redefined - A Consensus Document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction, Eur. Heart J., September 2000, pp. 1502-1513, Vol. 21, No. 18.	
	A125	TROUGHTON et al., Plasma B-Type Natriuretic Peptide Levels in Systolic Heart Failure, J. Am. Coll. Cardiol., February 4, 2004, pp. 416-22, Vol. 43, No. 3, Elsevier Inc.	
	A126	VILLAR-PALASI et al., Glycogen Metabolism and Glycolytic Enzymes, Annual Review of Biochemistry, 1970, pp. 639-672, Vol. 39.	
	A127	VILLARREAL et al., Effects of Meclofenamate on the Renin Response to Aortic Constriction in the Rat, American Journal of Physiology, September 1984, pp. R546-R551, Part 2 of Two Parts, Vol. 247, No. 3, The American Physiological Society.	
	A128	WEI et al., Pathophysiologic Concentrations of Human Brain natriuretic Peptide Have Functionally Important Biological Actions In Vivo, JASN, September 1991, p. 422, Abstract 73P, Vol. 2, No. 3.	
	A129	WILLGING et al., Specificity of Cardiac Troponins I and T in Renal Disease, Clin. Chem. Lab. Med., 1998, pp. 87-92, Vol. 36, No. 2.	
	A130	WRIGHT et al., Amino-Terminal Pro-C-Type Natriuretic Peptide in Heart Failure, Hypertension, January 2004, p. 94-100, Vol. 43.	
	A131	WRIGHT et al., Plasma Amino-terminal Pro-Brain Natriuretic Peptide and accuracy of Heart-Failure Diagnosis in Primary Care, J. Am. Coll. Cardiol., November 19, 2003, pp. 1793-1800, Vol. 42, No. 10, Elsevier Inc.	
	A132	WU A.H.B., Analytical and Clinical Evaluation of New Diagnostic Tests for Myocardial Damage, Clinica Chimica Acta, 1998, pp. 11-21, Vol. 272, Elsevier.	
	A133	YANDLE et al., Brain Natriuretic Peptide - Its Function and Diagnostic Application, Clin. Biochem. Rev., February 2002, pp. 3-21, Vol. 23.	
	A134	YASUE et al., Localization and Mechanism of Secretion of B-Type Natriuretic Peptide in Comparison with Those of A-Type Natriuretic Peptide in Normal Subjects and Patients with Heart Failure, circulation, July 1994, pp. 195-203, Vol. 90, No. 1.	

Examiner Signature		Date Considered	3/12/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.


⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: October 27, 2005 <i>(use as many sheets as necessary)</i>		Application Number	09/835,298
		Filing Date	04/13/2001
		First Named Inventor	Jeffrey R. Dahlen
		Group Art Unit	1641
		Examiner Name	Ann Y. Lam
Sheet 11 of 11	Attorney Docket Number	071949-5301	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A135	YOSHIMURA et al., Interaction on Metabolic Clearance Between A-type and B-type Natriuretic Peptides in Patients with Heart Failure, Metabolism, September 2000, pp. 1228-1233, Vol. 49, No. 9.	
	A136	YOSHIMURA et al., Responses of Plasma Concentrations of A Type Natriuretic Peptide and B Type Natriuretic Peptide to Alacepril, an Angiotensin-Converting Enzyme Inhibitor, in Patients with Congestive Heart Failure, Br. Heart J., 1994, pp. 528-533, Vol. 72.	
	A137	YU et al., Plasma Brain Natriuretic Peptide — An Independent Predictor of Cardiovascular Mortality in Acute Heart Failure, Eur. J. Heart Fail., 1999, pp. 59-65, Vol. 1.	
	A138	ZANOLLA et al., Selection of Endpoints for Heart Failure Clinical Trials, Eur. J. Heart Fail., 2003, pp. 717-723, Vol. 5, Elsevier B.V.	
	A139	ZIEBIG et al., Renal Elimination of Troponin T and Troponin I, Clinical Chemistry, 2003, pp. 1191-93, Vol. 49, No. 7.	
	A140	ZIESCHE et al., Interobserver Discordance in the Classification of Mechanisms of Death in Studies of Heart Failure, Journal of Cardiac Failure, March 1995, pp. 127-132, Vol. 1, No. 2.	
	A141	ZOCCALI et al., Cardiac Natriuretic Peptides are Related to Left Ventricular Mass and Function and Predict Mortality in Dialysis Patients, J. Am. Soc. Nephrol., 2001, pp. 1508-1515, Vol. 12.	


Examiner Signature		Date Considered	3/26/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/835,298
				Filing Date	04/13/2001
				First Named Inventor	DAHLEN
				Group Art Unit	1641
				Examiner Name	GABEE Lam
Sheet	1	of	1	Attorney Docket Number	071949-5301

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
RL	A1	Harter et al., Caspase-3 activity is present in cerebrospinal fluid from patients with traumatic brain injury. Journal of Neuroimmunology, 121:76-78, 2001.	

Examiner Signature		Date Considered	3/12/06
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/835,298
			Filing Date	04/13/2001
Sheet 1 of 1			First Named Inventor	Jeffrey R. Dahlen
			Group Art Unit	1641
			Examiner Name	G. Gabel Law
			Attorney Docket Number	071949-5301

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
JRE	A1	5352587		Chang et al.	10-04-1994	
	A2	5422393		Bricker et al.	06-06-1995	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
JRE	A3	International Search Report and the Written Opinion of the International Searching Authority from PCT Application No. PCT/US04/12024.	

RECEIVED
2004 DEC -5 PM 07
BOARD OF PATENT APPEALS
AND INTERFERENCES
TECH CENTER 1600 2900


Examiner Signature		Date Considered	3/12/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

 Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/835,298
		Filing Date	04/13/2001
		First Named Inventor	Jeffrey R. Dahlen
		Group Art Unit	1641
		Examiner Name	Lam, Ann Y.
		Attorney Docket Number	071949-5301
Sheet	1	of	2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1	WO	02/083913		Biosite Diagnostics, Inc.	10-24-2002		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	A2	CASSIN et al., <i>È realizzabile una strategia operative piu efficace per la gestione in urgenza del paziente con dolore toracico acuto?</i> , Ital Heart J Suppl, Feb. 2000, pp. 186-201, Vol. 1		
	A3	FUTTERMAN et al., <i>Novel Markers in the Acute Coronary Syndrome: BNP, IL-6, PAPP-A</i> , American Journal of Critical Care, March 2002, pp. 168-172, Vol. 11, No. 2		
	A4	HUNT et al., <i>Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment</i> , Clinical Endocrinology, 1997, pp. 287-296, Vol. 47		

Examiner Signature		Date Considered	3/12/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DLMR_279895.1

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use ⁸ as many sheets as necessary)

2 of 2

Complete if Known

Application Number	09/835,298
Filing Date	04/13/2001
First Named Inventor	Jeffrey R. Dahlen
Group Art Unit	1641
Examiner Name	Lam, Ann Y.
Attorney Docket Number	071949-5301

NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

3/12/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

DLMR_279895.1